Ultralife Temettüler ve Geri Alımlar

Temettü kriter kontrolleri 0/6

Ultralife şirketinin temettü ödeme geçmişi bulunmamaktadır.

Anahtar bilgiler

n/a

Temettü verimi

-1.7%

Geri Alım Getirisi

Toplam Hissedar Getirisi	-1.7%
Gelecekteki Temettü Verimi	n/a
Temettü Büyümesi	n/a
Bir sonraki temettü ödeme tarihi	n/a
Eski temettü tarihi	n/a
Hisse başına temettü	n/a
Ödeme oranı	n/a

Son temettü ve geri alım güncellemeleri

Güncelleme yok

Recent updates

These 4 Measures Indicate That Ultralife (NASDAQ:ULBI) Is Using Debt Reasonably Well

Apr 16

Slowing Rates Of Return At Ultralife (NASDAQ:ULBI) Leave Little Room For Excitement

Mar 14

Insufficient Growth At Ultralife Corporation (NASDAQ:ULBI) Hampers Share Price

Feb 11

Is Now An Opportune Moment To Examine Ultralife Corporation (NASDAQ:ULBI)?

Oct 26

Ultralife (NASDAQ:ULBI) May Have Issues Allocating Its Capital

Sep 22

Ultralife (NASDAQ:ULBI) Takes On Some Risk With Its Use Of Debt

Jun 08

Ultralife (NASDAQ:ULBI) Is Carrying A Fair Bit Of Debt

Sep 27

Ultralife secures $7.5M communications systems contract

Sep 22

Ultralife receives $4.6M communications systems VAA order

Jul 26

Does Ultralife (NASDAQ:ULBI) Have A Healthy Balance Sheet?

Apr 15

We Think Ultralife Corporation's (NASDAQ:ULBI) CEO Compensation Package Needs To Be Put Under A Microscope

Jul 15

Is Ultralife Corporation (NASDAQ:ULBI) Potentially Undervalued?

Apr 14

The Trends At Ultralife (NASDAQ:ULBI) That You Should Know About

Mar 09

Ultralife Corporation's (NASDAQ:ULBI) Stock On An Uptrend: Could Fundamentals Be Driving The Momentum?

Feb 18

Ultralife reports Q4 results

Feb 04

If You Had Bought Ultralife (NASDAQ:ULBI) Stock Five Years Ago, You Could Pocket A 17% Gain Today

Feb 03

Ödemelerde İstikrar ve Büyüme

Temettü verilerini getirme

İstikrarlı Temettü: ULBI şirketinin hisse başına düşen temettülerinin geçmişte istikrarlı olup olmadığını belirlemek için yeterli veri yok.

Büyüyen Temettü: ULBI şirketinin temettü ödemelerinin artıp artmadığını belirlemek için yeterli veri yok.

Piyasaya Karşı Temettü Getirisi

Ultralife Piyasaya Karşı Temettü Getirisi

ULBI temettü verimi piyasa ile karşılaştırıldığında nasıldır?
Segment	Temettü Verimi
Şirket (ULBI)	n/a
Pazarın Alt %25'i (US)	1.4%
Pazarın En İyi %25'i (US)	4.2%
Sektör Ortalaması (Electrical)	1.0%
Analist tahmini (ULBI) (3 yıla kadar)	n/a

Önemli Temettü: ULBI şirketinin temettü getirisi, şirketin yakın zamanda herhangi bir ödeme bildirmemesi nedeniyle, temettü ödeyenlerin en alttaki %25'lik dilimine göre değerlendirilemiyor.

Yüksek Temettü: Şirketin yakın zamanda herhangi bir ödeme bildirmemesi nedeniyle, ULBI şirketinin temettü getirisi, temettü ödeyenlerin en üst %25'ine göre değerlendirilemiyor.

Hissedarlara Ödenen Kazanç

Kazanç Kapsamı: ULBI şirketinin temettü ödemelerinin kazançlarla karşılanıp karşılanmadığını belirlemek için ödeme oranını hesaplamak üzere yeterli veri yok.

Hissedarlara Nakit Ödeme

Nakit Akışı Kapsamı: ULBI herhangi bir ödeme bildirmediğinden temettülerin sürdürülebilirliği hesaplanamıyor.

Ultralife Temettüler ve Geri Alımlar

Temettü kriter kontrolleri 0/6

Anahtar bilgiler

Son temettü ve geri alım güncellemeleri

Recent updates

Ultralife Corporation to Report Q3, 2024 Results on Nov 08, 2024

Ultralife Corporation (NasdaqGM:ULBI) signed a stock purchase agreement to acquire Electrochem Solutions, Inc. from Integer Holdings Corporation (NYSE:ITGR) for $50 million.

Should You Think About Buying Ultralife Corporation (NASDAQ:ULBI) Now?

Ultralife: I Bought The Dip; Here Comes The Growth

Ultralife's (NASDAQ:ULBI) Earnings Are Weaker Than They Seem

Ultralife Corporation to Report Q2, 2024 Results on Jul 25, 2024

Ultralife Corporation Is Attractive Here

Ultralife Corporation, Annual General Meeting, Jul 16, 2024

Investor sentiment improves as stock rises 17%

Price target decreased by 7.7% to US$12.00

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

Ultralife Corporation: Ready To Surge

These 4 Measures Indicate That Ultralife (NASDAQ:ULBI) Is Using Debt Reasonably Well

Ultralife Corporation to Report Q1, 2024 Results on Apr 25, 2024

Full year 2023 earnings released: EPS: US$0.44 (vs US$0.007 loss in FY 2022)

Slowing Rates Of Return At Ultralife (NASDAQ:ULBI) Leave Little Room For Excitement

Full year 2023 earnings released: EPS: US$0.44 (vs US$0.007 loss in FY 2022)

Investor sentiment improves as stock rises 15%

Insufficient Growth At Ultralife Corporation (NASDAQ:ULBI) Hampers Share Price

New major risk - Revenue and earnings growth

Ultralife Corporation to Report Q4, 2023 Results on Feb 15, 2024

Independent Chairman recently bought US$111k worth of stock

Independent Chairman recently bought US$181k worth of stock

Independent Chairman recently bought US$99k worth of stock

Investor sentiment deteriorates as stock falls 19%

Third quarter 2023 earnings: Revenues and EPS in line with analyst expectations

Is Now An Opportune Moment To Examine Ultralife Corporation (NASDAQ:ULBI)?

Ultralife Corporation to Report Q3, 2023 Results on Oct 26, 2023

Investor sentiment improves as stock rises 18%

Ultralife (NASDAQ:ULBI) May Have Issues Allocating Its Capital

Independent Chairman recently bought US$112k worth of stock

Investor sentiment improves as stock rises 27%

Consensus revenue estimates increase by 12%

New major risk - Share price stability

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Ultralife Corporation to Report Q2, 2023 Results on Jul 27, 2023

Independent Chairman recently bought US$398k worth of stock

Ultralife (NASDAQ:ULBI) Takes On Some Risk With Its Use Of Debt

Independent Chairman recently bought US$146k worth of stock

Ultralife Corporation, Annual General Meeting, Jul 19, 2023

Independent Chairman recently bought US$117k worth of stock

Full year 2022 earnings released: US$0.007 loss per share (vs US$0.015 loss in FY 2021)

Independent Chairman recently bought US$122k worth of stock

Full year 2022 earnings released: US$0.007 loss per share (vs US$0.015 loss in FY 2021)

Independent Chairman recently bought US$279k worth of stock

Ultralife Corporation Announces Executive Changes

Price target increased to US$12.00

Insufficient new directors

Third quarter 2022 earnings: EPS misses analyst expectations

Ultralife Corporation to Report Q3, 2022 Results on Oct 27, 2022

Ultralife (NASDAQ:ULBI) Is Carrying A Fair Bit Of Debt

Ultralife secures $7.5M communications systems contract

Independent Chairman recently bought US$158k worth of stock

Independent Chairman recently bought US$467k worth of stock

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

Ultralife receives $4.6M communications systems VAA order

Ultralife Corporation to Report Q2, 2022 Results on Jul 28, 2022

Independent Chairman recently bought US$219k worth of stock

Ultralife Corporation, Annual General Meeting, Jul 20, 2022

First quarter 2022 earnings: EPS and revenues exceed analyst expectations

Insufficient new directors

Ultralife Corporation to Report Q1, 2022 Results on Apr 28, 2022

Does Ultralife (NASDAQ:ULBI) Have A Healthy Balance Sheet?

Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

Independent Chairman recently bought US$245k worth of stock

Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

Consensus revenue estimates fall by 14%

Investor sentiment improved over the past week

Ultralife Corporation (NasdaqGM:ULBI) acquired Excell Battery Company for $23.5 million.

Third quarter 2021 earnings released: US$0.036 loss per share (vs US$0.026 profit in 3Q 2020)

Independent Chairman recently bought US$199k worth of stock

Second quarter 2021 earnings released: EPS US$0.051 (vs US$0.10 in 2Q 2020)

We Think Ultralife Corporation's (NASDAQ:ULBI) CEO Compensation Package Needs To Be Put Under A Microscope

Ultralife Corporation(NasdaqGM:ULBI) dropped from Russell 2000 Defensive Index

Investor sentiment improved over the past week